Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia
Restricted accessResearch articleFirst published online October 18, 2016
Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia
Background: Correctly diagnosing Alzheimer’s disease (AD) in prodromal phases would allow the adoption of experimental therapeutic strategies that could selectively interrupt the pathogenetic process before neuronal damage becomes irreversible. Therefore, great efforts have been aimed at finding early reliable disease markers.
Objective: The aim of this study was to identify a simple, cost effective, and reliable diagnostic algorithm to predict conversion from mild cognitive impairment (MCI) to AD.
Methods: 96 consecutive MCI patients admitted to the Neurology department of San Raffaele Hospital in Milan between January 2009 and January 2015 were included. All patients underwent neuropsychological assessment and lumbar puncture with CSF analysis of amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels. Each patient underwent clinical and neuropsychological follow-up, in order to identify a possible progression from MCI to AD. The mean follow up time was 36.73 months.
Results: 37 out of 96 MCI converted to AD during follow up. CSF analysis and neuropsychological assessment reliably detected MCI patients who developed AD. In a subsample of 43 subjects, a Composite Cognitive Score (CCS) was calculated including episodic memory, executive function, and verbal fluency tests. Combining together CSF biomarkers and CCS increased the accuracy of the single predictors, correctly classifying 86% of patients with a specificity of 96% and a Positive Predictive Value of 93%.
Discussion: Even if preliminary, our data seem to suggest that CSF analysis and neuropsychological assessment could detect MCI patients who will convert to AD with high confidence. Their relative low cost and availability could make them worldwide essential tools in future clinical trials.
RafiiMS, AisenPS (2015) Advances in Alzheimer’s disease drug development. BMC Med13, 62.
7.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’brienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
8.
AshfordJW, BorsonS, O’HaraR, DashP, FrankL, RobertP, ShankleWR, TierneyMC, BrodatyH, SchmittFA, KraemerHC, BuschkeH, FillitH (2007) Should older adults be screened for dementia? It is important to screen for evidence of dementia!. Alzheimers Dement3, 75–80.
9.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
10.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
11.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DekoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, de SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaS-K, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosénE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttiläT, WallinA, JönhagenME, MinthonL, WinbladB, BlennowK (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385–393.
14.
HanssonO, ZetterbergH, BuchhaveP, LondosE, BlennowK, MinthonL (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol5, 228–234.
15.
BlennowK (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx1, 213–225.
16.
HampelH, BürgerK, TeipelSJ, BokdeALW, ZetterbergH, BlennowK (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement4, 38–48.
17.
CoppiE, FerrariL, SantangeloR, CasoF, PintoP, PasseriniG, ComiG, MagnaniG (2014) Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy. Neurol Sci35, 785–787.
18.
SantangeloR, CoppiE, FerrariL, BernasconiMP, PintoP, PasseriniG, ComiG, MagnaniG (2015) Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. J Alzheimers Dis43, 1429–1440.
19.
DinizBS, Pinto JúniorJA, ForlenzaOV (2007) Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry9, 172–182.
20.
DaX, ToledoJB, ZeeJ, WolkDA, XieSX, OuY, ShacklettA, ParmpiP, ShawL, TrojanowskiJQ, DavatzikosC (2014) Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin4, 164–173.
21.
AndreasenN, VanmechelenE, VandersticheleH, DavidssonP, BlennowK (2003) Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment. Acta Neurol Scand107, 47–51.
22.
SchmandB, HuizengaHM, van GoolWA (2010) Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. Psychol Med40, 135–145.
23.
ArnáizE, AlmkvistO (2003) Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease. Acta Neurol Scand Suppl179, 34–41.
24.
NewmanSK, WarringtonEK, KennedyAM, RossorMN (1994) The earliest cognitive change in a person with familial Alzheimer’s disease: Presymptomatic neuropsychological features in a pedigree with familial Alzheimer’s disease confirmed at necropsy. J Neurol Neurosurg Psychiatry57, 967–972.
25.
JacobsDM, SanoM, DooneiefG, MarderK, BellKL, SternY (1995) Neuropsychological detection and characterization of preclinical Alzheimer’s disease. Neurology45, 957–962.
26.
MasurDM, SliwinskiM, LiptonRB, BlauAD, CrystalHA (1994) Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology44, 1427–1432.
27.
SmallBJ, HerlitzA, FratiglioniL, AlmkvistO, BäckmanL (1997) Cognitive predictors of incident Alzheimer’s disease: A prospective longitudinal study. Neuropsychology11, 413–420.
28.
EckerströmC, OlssonE, BjerkeM, MalmgrenH, EdmanA, WallinA, NordlundA (2013) A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. J Alzheimers Dis36, 421–431.
GriffithHR, NetsonKL, HarrellLE, ZamriniEY, BrockingtonJC, MarsonDC (2006) Amnestic mild cognitive impairment: Diagnostic outcomes and clinical prediction over a two-year time period. J Int Neuropsychol Soc12, 166–175.
31.
EwersM, WalshC, TrojanowskiJQ, ShawLM, PetersenRC, JackCR, FeldmanHH, BokdeALW, AlexanderGE, ScheltensP, VellasB, DuboisB, WeinerM, HampelH, North American Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2012) Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging33, 1203–1214.
32.
DavangereP, DevanandXL (2008) Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry64, 871–879.
33.
CuiY, LiuB, LuoS, ZhenX, FanM, LiuT, ZhuW, ParkM, JiangT, JinJS, Alzheimer’s Disease Neuroimaging, Initiative (2011) Identification of conversion from mild cognitive impairment to Alzheimer’s disease using multivariate predictors. PloS One6, e21896.
34.
KatzS, FordAB, MoskowitzRW, JacksonBA, JaffeMW (1963) Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA185, 914–919.
35.
LawtonMP, BrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist9, 179–186.
36.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
37.
MagniE, BinettiG, BianchettiA, RozziniR, TrabucchiM (1996) Mini-Mental State Examination: A normative study in Italian elderly population. Eur J Neurol3, 198–202.
38.
HughesCP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br. J Psychiatry J Ment Sci140, 566–572.
39.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
40.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundL-O, NordbergA, BäckmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, De LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, Van DuijnC, VisserP, PetersenR c (2004) Mild cognitive impairment –beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
41.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
42.
MauriM, CarlesimoGA, GraceffaAMS, LoassesA, LorussoS, SinforianiE, BonoG, CaltagironeC (1997) Standardizzazione di due nuovi test di memoria: Apprendimento di liste di parole correlate e non correlate semanticamente. Arch Psicol Neurol Psichiatr58, 621–645.
43.
NovelliG, PapagnoC, CapitaniE, LaiaconaM, CappaSF, VallarG (1986) Tre test clinici di memoria verbale a lungo termine: Taratura su soggetti normali. [Three clinical tests for the assessment of verbal long-term memory function: Norms from 320 normal subjects.]. Arch Psicol Neurol Psichiatr47, 278–296.
44.
SpinnlerH, TognoniG (1987) Standardizzazione e taratura italiana di test neuropsicologici: Gruppo italiano per lo studio neuropsicologico dell’invecchiamento,Masson Italia Periodici, Milano.
45.
GiovagnoliAR, Del PesceM, MascheroniS, SimoncelliM, LaiaconaM, CapitaniE (1996) Trail making test: Normative values from 287 normal adult controls. Ital J Neurol Sci17, 305–309.
46.
BassoA, CapitaniE, LaiaconaM (1987) Raven’s coloured progressive matrices: Normative values on 305 adult normal controls. Funct Neurol2, 189–194.
47.
SjögrenM, VandersticheleH, AgrenH, ZachrissonO, EdsbaggeM, WikkelsøC, SkoogI, WallinA, WahlundLO, MarcussonJ, NäggaK, AndreasenN, DavidssonP, VanmechelenE, BlennowK (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem47, 1776–1781.
48.
TapiolaT, AlafuzoffI, HerukkaS-K, ParkkinenL, HartikainenP, SoininenH, PirttiläT (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol66, 382–389.
49.
de JongD, JansenRWMM, KremerBPH, VerbeekMM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci61, 755–758.
50.
RománGC, TatemichiTK, ErkinjunttiT, CummingsJL, MasdeuJC, GarciaJH, AmaducciL, OrgogozoJM, BrunA, HofmanA (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology43, 250–260.
WardA, TardiffS, DyeC, ArrighiHM (2013) Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: A systematic review of the literature. Dement Geriatr Cogn Disord EXTRA3, 320–332.
55.
HortJ, BartosA, PirttiläT, ScheltensP (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol17, 90–96.
56.
VerweyNA, van der FlierWM, BlennowK, ClarkC, SokolowS, De DeynPP, GalaskoD, HampelH, HartmannT, KapakiE, LannfeltL, MehtaPD, ParnettiL, PetzoldA, PirttilaT, SalehL, SkinningsrudA, SwietenJC, VerbeekMM, WiltfangJ, YounkinS, ScheltensP, BlankensteinMA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem46, 235–240.
FerreiraD, Perestelo-PérezL, WestmanE, WahlundL-O, SarríaA, Serrano-AguilarP (2014) Meta-review of CSF core biomarkers in Alzheimer’s disease: The state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci6, 47.
59.
PalmqvistS, HertzeJ, MinthonL, WattmoC, ZetterbergH, BlennowK, LondosE, HanssonO (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: six-year follow-up study. PLoS One7, e38639.
60.
MattssonN, BlennowK, ZetterbergH (2009) CSF biomarkers: Pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci1180, 28–35.
61.
BuchhaveP, MinthonL, ZetterbergH, WallinAK, BlennowK, HanssonO (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry69, 98–106.
62.
van RossumIA, VosS, HandelsR, VisserPJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: Implications for trial design. J Alzheimers Dis20, 881–891.
63.
ParnettiL, ChiasseriniD, EusebiP, GiannandreaD, BellomoG, De CarloC, PadiglioniC, MastrocolaS, LisettiV, CalabresiP (2012) Performance of Aβ1-40, Aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis29, 229–238.
64.
GaserC, FrankeK, KlöppelS, KoutsoulerisN, SauerH, Alzheimer’s Disease Neuroimaging, Initiative (2013) BrainAGE in mild cognitive impaired patients: Predicting the conversion to Alzheimer’s disease. PloS One8, e67346.
65.
HertzeJ, MinthonL, ZetterbergH, VanmechelenE, BlennowK, HanssonO (2010) Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: A clinical follow-up study of 4.7 years. J Alzheimers Dis21, 1119–1128.
66.
AmievaH, Jacqmin-GaddaH, OrgogozoJ-M, Le CarretN, HelmerC, LetenneurL, Barberger-GateauP, FabrigouleC, DartiguesJ-F (2005) The 9 year cognitive decline before dementia of the Alzheimer type: A prospective population-based study. Brain128, 1093–1101.
67.
JohnsonDK, StorandtM, MorrisJC, GalvinJE (2009) Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol66, 1254–1259.
68.
SmallBJ, BäckmanL (2007) Longitudinal trajectories of cognitive change in preclinical Alzheimer’s disease: A growth mixture modeling analysis. Cortex43, 826–834.
69.
GroberE, HallCB, LiptonRB, ZondermanAB, ResnickSM, KawasC (2008) Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. J Int Neuropsychol Soc14, 266–278.
70.
HowiesonDB, CarlsonNE, MooreMM, WassermanD, AbendrothCD, Payne-MurphyJ, KayeJA (2008) Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc14, 192–198.
71.
WilsonRS, LeurgansSE, BoylePA, BennettDA (2011) Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol68, 351–356.
72.
AmievaH, LeGoff M, MilletX, OrgogozoJM, PérèsK, Barberger-GateauP, Jacqmin-GaddaH, DartiguesJF (2008) Prodromal Alzheimer’s disease: Successive emergence of the clinical symptoms. Ann Neurol64, 492–498.
73.
EliasMF, BeiserA, WolfPA, AuR, WhiteRF, D’AgostinoRB (2000) The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol57, 808–813.
74.
GrundmanM, PetersenRC, FerrisSH, ThomasRG, AisenPS, BennettDA, FosterNL, JackCR, GalaskoDR, DoodyR, KayeJ, SanoM, MohsR, GauthierS, KimHT, JinS, SchultzAN, SchaferK, MulnardR, van DyckCH, MintzerJ, ZamriniEY, Cahn-WeinerD, ThalLJ, Alzheimer’s Disease Cooperative, Study (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol61, 59–66.
75.
MitchellJ, ArnoldR, DawsonK, NestorPJ, HodgesJR (2009) Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm. J Neurol256, 1500–1509.
DierckxE, EngelborghsS, De RaedtR, Van BuggenhoutM, De DeynPP, VertéD, Ponjaert-KristoffersenI (2009) Verbal cued recall as a predictor of conversion to Alzheimer’s disease in mild cognitive impairment. Int J Geriatr Psychiatry24, 1094–1100.
78.
SarazinM, BerrC, De RotrouJ, FabrigouleC, PasquierF, LegrainS, MichelB, PuelM, VolteauM, TouchonJ, VernyM, DuboisB (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology69, 1859–1867.
KlagesJD, FiskJD, RockwoodK (2005) APOE genotype, vascular risk factors, memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer’s disease. Dement Geriatr Cogn Disord20, 292–297.
81.
AretouliE, TsilidisKK, BrandtJ (2013) Four-year outcome of mild cognitive impairment: The contribution of executive dysfunction. Neuropsychology27, 95–106.
82.
BrandtJ, AretouliE, NeijstromE, SamekJ, ManningK, AlbertMS, Bandeen-RocheK (2009) Selectivity of executive function deficits in mild cognitive impairment. Neuropsychology23, 607–618.
83.
BellevilleS, GauthierS, LepageE, KergoatM-J, GilbertB (2014) Predicting decline in mild cognitive impairment: A prospective cognitive study. Neuropsychology28, 643–652.
84.
BickelH, MoschE, SeigerschmidtE, SiemenM, ForstlH (2006) Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dement Geriatr Cogn Disord21, 242–250.
85.
BondiMW, JakAJ, Delano-WoodL, JacobsonMW, DelisDC, SalmonDP (2008) Neuropsychological contributions to the early identification of Alzheimer’s disease. Neuropsychol Rev18, 73–90.
86.
BusseA, HenselA, GühneU, AngermeyerMC, Riedel-HellerSG (2006) Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology67, 2176–2185.
87.
ZanettiM, BallabioC, AbbateC, CutaiaC, VerganiC, BergamaschiniL (2006) Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: A 3-year follow-up study. J Am Geriatr Soc54, 580–586.
JakAJ, BondiMW, Delano-WoodL, WierengaC, Corey-BloomJ, SalmonDP, DelisDC (2009) Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry17, 368–375.
90.
RajanKB, WilsonRS, WeuveJ, BarnesLL, EvansDA (2015) Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology85, 898–904.
91.
AyutyanontN, LangbaumJB, HendrixSB, ChenK, FleisherAS, FriesenhahnM, WardM, AguirreC, Acosta-BaenaN, MadrigalL, MuñozC, TiradoV, MorenoS, TariotPN, LoperaF, ReimanEM (2014) The Alzheimer’s Prevention Initiative composite cognitive test score: Sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry75, 652–660.
92.
LangbaumJB, HendrixSB, AyutyanontN, ChenK, FleisherAS, ShahRC, BarnesLL, BennettDA, TariotPN, ReimanEM (2014) An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease. Alzheimers Dement10, 666–674.
